Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL

Authors: Isabelle Bartram, Ulrike Erben, Jutta Ortiz-Tanchez, Katja Blunert, Cornelia Schlee, Martin Neumann, Sandra Heesch, Claudia D. Baldus

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease with the need for treatment optimization. Previously, high expression of Insulin-like growth factor binding protein 7 (IGFBP7), a member of the IGF system, was identified as negative prognostic factor in adult T-ALL patients. Since aberrant IGFBP7 expression was observed in a variety of neoplasia and was relevant for prognosis in T-ALL, we investigated the functional role of IGFBP7 in Jurkat and Molt-4 cells as in vitro models for T-ALL.

Methods

Jurkat and Molt-4 cells were stably transfected with an IGFBP7 over-expression vector or the empty vector as control. Proliferation of the cells was assessed by WST-1 assays and cell cycle status was measured by flow-cytometry after BrDU/7-AAD staining. The effect of IGFBP7 over-expression on sensitivity to cytostatic drugs was determined in AnnexinV/7-AAD assays. IGF1-R protein expression was measured by Western Blot and flow-cytometric analysis. IGF1-R associated gene expression profiles were generated from microarray gene expression data of 86 T-ALL patients from the Microarrays Innovations in Leukemia (MILE) multicenter study.

Results

IGFBP7-transfected Jurkat cells proliferated less, leading to a longer survival in a nutrient–limited environment. Both IGFBP7-transfected Jurkat and Molt-4 cells showed an arrest in the G0/G1 cell cycle phase. Furthermore, Jurkat IGFBP7-transfected cells were resistant to vincristine and asparaginase treatment. Surface expression and whole protein measurement of IGF1-R protein expression showed a reduced abundance of the receptor after IGFBP7 transfection in Jurkat cells. Interestingly, combination of the IGF1-R inhibitor NPV-AEW541 restored sensitivity to vincristine in IGFBP7-transfected cells. Additionally, IGF1-R associated GEP revealed an up-regulation of important drivers of T-ALL pathogenesis and regulators of chemo-resistance and apoptosis such as NOTCH1, BCL-2, PRKCI, and TP53.

Conclusion

This study revealed a proliferation inhibiting effect of IGFBP7 by G0/G1 arrest and a drug resistance-inducing effect of IGFBP7 against vincristine and asparaginase in T-ALL. These results provide a model for the previously observed association between high IGFBP7 expression and chemotherapy failure in T-ALL patients. Since the resistance against vincristine was abolished by IGF1-R inhibition, IGFBP7 could serve as biomarker for patients who may benefit from therapies including IGF1-R inhibitors in combination with chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46:64–75.CrossRefPubMed
2.
Hunault M, Harousseau J-L, Delain M, Truchan-Graczyk M, Cahn J-Y, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028–37.CrossRefPubMed
3.
4.
Hwa V, Oh Y, Rosenfeld R. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20:761–87.PubMed
5.
Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol - Endocrinol Metab. 2000;278:E967–76.PubMed
6.
Ingermann AR, Yang Y, Han J, Mikami A, Garza AE, Mohanraj L, et al. Identification of a Novel Cell Death Receptor Mediating IGFBP-3-induced Antitumor Effects in Breast and Prostate Cancer. J Biol Chem. 2010;285:30233–46.CrossRefPubMedPubMedCentral
7.
Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and −5 is mediated by the importin beta subunit. J Biol Chem. 2000;275:23462–70.CrossRefPubMed
8.
Azar WJ, Zivkovic S, Werther GA, Russo VC. IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene. 2014;33:578–88.CrossRefPubMed
9.
Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, Burger AM, et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene. 2001;20:3497–505.CrossRefPubMed
10.
Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, et al. IGFBP7 Plays a Potential Tumor Suppressor Role in Colorectal Carciogenesis. Cancer Biol Ther. 2007;6:354–9.CrossRefPubMed
11.
Tomimaru Y, Enguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, et al. IGFBP7 downregulation is associated with tumor supression and clinical outcome in heptocellular carcinoma. Int J Cancer. 2012;130:319–27.CrossRefPubMed
12.
Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen X-N, et al. Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther. 2013;21:758–66.CrossRefPubMedPubMedCentral
13.
Chen R-Y, Chen H-X, Lin J-X, She W-B, Jiang P, Xu L, et al. In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression. J Exp Clin Cancer Res. 2010;29:13.CrossRefPubMedPubMedCentral
14.
Chen R-Y, Chen H-X, Jian P, Xu L, Li J, Fan Y-M, et al. Intratumoral injection of pEGFC1-IGFBP7 inhibits malignant melanoma growth in C57BL/6 J mice by inducing apoptosis and down-regulating VEGF expression. Oncol Rep. 2010;23:981–8.PubMed
15.
Heesch S, Schlee C, Neumann M, Stroux A, Kühnl A, Schwartz S, et al. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia. 2010;24:1429–36.CrossRefPubMed
16.
Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2012;133:563–73.CrossRefPubMed
17.
Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 2010;29:3835–44.CrossRefPubMed
18.
Zuo S, Liu C, Wang J, Wang F, Xu W, Cui S, et al. IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol. 2012;138:1045–55.CrossRefPubMed
19.
Ma Y, Lu B, Ruan W, Wang H, Lin J, Hu H, et al. Tumor suppressor gene insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) induces senescence-like growth arrest in colorectal cancer cells. Exp Mol Pathol. 2008;85:141–5.CrossRefPubMed
20.
Hu S, Chen R, Man X, Feng X, Cen J, Gu W, et al. Function and expression of insulin-like growth factor-binding protein 7 (IGFBP7) gene in childhood acute myeloid leukemia. Pediatr Hematol Oncol. 2011;28:279–87.CrossRefPubMed
21.
Laranjeira AB, De Vasconcellos JF, Sodek L, Spago MC, Fornazim MC, Tone LG, et al. IGFBP7 Participates in the Reciprocal Interaction between Acute Lymphoblastic Leukemia and BM Stromal Cells and in Leukemia Resistance to Asparaginase. Leukemia. 2012;26:1001–11.CrossRefPubMed
22.
Bohne A, Schlee C, Mossner M, Thibaut J, Heesch S, Thiel E, et al. Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leuk Res. 2009;33:817–22.CrossRefPubMed
23.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.CrossRefPubMed
24.
Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te KG, Béné M-C, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28:2529–37.CrossRefPubMed
25.
Anderson MA, Huang D, Roberts A. Targeting BCL2 for the Treatment of Lymphoid Malignancies. Semin Hematol. 2014;51:219–27.CrossRefPubMed
26.
Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, et al. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol. 2013;44:1017–23.CrossRefPubMed
27.
Roszak J, Smok-Pienia̧zek A, Nocuń M, Stȩpnik M. Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: Focus on PI3K/Akt signaling pathway. Chem Biol Interact. 2013;205:198–211.CrossRefPubMed
28.
Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol. 2013;792:109–31.CrossRefPubMed
29.
Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. Cell. 2007;129:879–90.CrossRefPubMedPubMedCentral
30.
Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009;1:253-361
31.
Lee DW, Zhang K, Ning ZQ, Raabe EH, Tintner S, Wieland R, et al. Proliferation-associated SNF2-like gene (PASG): A SNF2 family member altered in leukemia. Cancer Res. 2000;60:3612–22.PubMed
32.
Shah MA, Schwartz GK. Cell Cycle-mediated Drug Resistance : An Emerging Concept in Cancer Therapy Cell Cycle-mediated Drug Resistance : An Emerging Concept in. Clin Cancer Res. 2001;7:2168–81.PubMed
33.
Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal. 2012;5:ra92.CrossRefPubMed
34.
Verhagen HJ, De Leeuw DC, Roemer MG, Denkers F, Pouwels W, Rutten A, et al. IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death Dis. 2014;5:e1300.CrossRefPubMedPubMedCentral
35.
He Y, Zhang J, Zheng J, Du W, Xiao H, Liu W, et al. The Insulin-Like Growth Factor-1 Receptor Kinase Inhibitor, NVP-ADW742, Suppresses Survival and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells. Oncol Res Featur Preclin Clin Cancer Ther. 2010;19:35–43.
36.
Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia. 2007;21:886–96.PubMed
37.
Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia. 2007;21:1921–30.CrossRefPubMed
38.
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28:3009–21.CrossRefPubMed
39.
Medyouf H, Gusscott S, Wang H, Tseng J-C, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208:1809–22.CrossRefPubMedPubMedCentral
40.
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71.CrossRefPubMed
41.
Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995;7:541–6.CrossRefPubMed
42.
Singleton JR, Dixit VM, Feldman EL. Type I Insulin-like Growth Factor Receptor Activation Regulates Apoptotic Proteins. J Biol Chem. 1996;271:31791–4.CrossRefPubMed
43.
Basu S, Rajakaruna S, Menko AS. Insulin-like growth factor receptor-1 and nuclear factor κB are crucial survival signals that regulate caspase-3-mediated lens epithelial cell differentiation initiation. J Biol Chem. 2012;287:8384–97.CrossRefPubMedPubMedCentral
44.
Metadata
Title
Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL
Authors
Isabelle Bartram
Ulrike Erben
Jutta Ortiz-Tanchez
Katja Blunert
Cornelia Schlee
Martin Neumann
Sandra Heesch
Claudia D. Baldus
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1677-z

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Study protocol

Early Palliative Care—Health services research and implementation of sustainable changes: the study protocol of the EVI project

Research article

Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

Research article

Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis

Research article

STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells

Research article

Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression

Research article

Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits